
TaibUVID for Minimizing COVID-19 Fatalities and Morbidity
An Evidence-based Approach for Better Outcomes (A Treatment Protocol)
Developing and poor countries may face humanity disasters in the next few days unless urgent measures are rapidly performed. Standard anti-COVID-19 treatment should inhibit COVID-19 replication, repair virus-induced tissue damage and enhance patients' immunity. Unfortunately, such criteria are still lacking in current treatments resulting in relatively high viral infectivity, morbidity and mortality.
Based on previous prophetic medicine research experience and the literature, we introduce TaibUVID therapy as a novel medicinal nutrition formulation. TaibUVID stands for Taibah University anti-COVID-19 treatment as a novel evidence-based approach (using natural products) for treating COVID-19 patients.
A single TaibUVID dose includes: 1 large spoonful of nigella sativa oil (or 2 gram nigella sativa seeds) mixed with 1 gram of grinded anthemis hyaline and 1 large spoonful of natural honey. This mixture is to be chewed in the mouth and swallowed orally for both COVID-19 contacts and patients. We adjusted dosing regimen and period of treatment into three clinical levels including contacts or prophylaxis, mild cases and severe case.
In addition, nigella sativa enhances immunity, exerts tissue protective effects and effectively treats co-morbidities. Oral honey exerts potent antiviral effects, enhances immunity and exerts tissue protective effects. Our suggested TaibUVID is a promising evidencebased approach to rescue lives, decrease fatalities and put a rapid end to COVID-19 pandemic.